Home / Peptides / Compare / BPC-157 vs TB-500
Comparison

BPC-157 vs TB-500

BPC-157 and TB-500 are the two most-referenced tissue-repair peptides, and the most common question is not which one — it is whether to study them separately or together. They arrive at repair from different directions: BPC-157 is a gastric-derived pentadecapeptide studied for local cytoprotective and healing signalling, while TB-500 is a fragment of thymosin beta-4, an actin-regulating protein involved in cell migration. Both carry extensive animal-model literatures and neither has completed human trials — an honest comparison is mostly about mechanism and evidence type, not proven outcomes.

View BPC-157 pens →
AttributeBPC-157TB-500
What it isSynthetic pentadecapeptide derived from a gastric protective proteinSynthetic fragment of thymosin beta-4 (Tβ4), an actin-binding protein
Studied mechanismLocal cytoprotection, angiogenesis and tendon/ligament/GI healing signallingActin regulation, cell migration and wound-site recruitment
Evidence baseLarge preclinical/animal literature; minimal human dataPreclinical wound-healing and cardiac models (as Tβ4); minimal human data
Regulatory statusNot an approved medicine anywhere; FDA has flagged insufficient human safety dataNot an approved medicine anywhere
Typical research focusTendon, ligament, muscle and gut injury modelsSoft-tissue repair, flexibility, cardiac models
WADA statusProhibited in competitive sportProhibited in competitive sport (TB-500/Tβ4 named)
How it is supplied hereCombined BPC-157 + TB-500 pen (single blend)Combined BPC-157 + TB-500 pen (single blend)

Different routes to the same goal

BPC-157 is studied as a locally acting healing signal — most of its animal literature involves injury models where it is applied near the damage (tendon, ligament, muscle, gastrointestinal tissue). TB-500 works further upstream: thymosin beta-4 regulates actin, the structural protein cells use to move, which is why its research profile centres on cell migration into wound sites. The mechanistic difference is the entire rationale for studying them together — one hypothesis for recruitment, one for local repair signalling.

What the evidence actually supports

Both compounds have consistent, repeated animal-model results — and that is where the confident claims must stop. Neither has completed a controlled human trial programme, neither has an approved dose, and the FDA has specifically flagged BPC-157 as lacking sufficient human safety information. Community protocols are conventions built on animal extrapolation, not clinical standards.

Solo vs stack

Reported research protocols dose the two compounds at different amounts and frequencies, which a fixed 1:1 blend cannot reproduce — the honest trade-off of any combined format. What a single pre-loaded blend does offer is consistency: one sealed solution at a printed concentration rather than two vials reconstituted separately. Which matters more depends on whether your research question needs per-compound precision or a stable combined exposure.

Frequently asked questions

Which is better for tendon research, BPC-157 or TB-500?

The tendon/ligament animal literature is larger for BPC-157; TB-500 features more in general soft-tissue and cardiac models. Neither has human trial evidence, so "better" can only describe the preclinical record.

Why are they usually studied together?

Their hypothesised mechanisms are complementary — TB-500 relates to cell migration into damaged tissue, BPC-157 to local repair signalling. The combination hypothesis dominates the research conversation, which is why combined formats exist.

Is either compound approved?

No. Neither BPC-157 nor TB-500 is an approved medicine in any jurisdiction, and both are prohibited in competitive sport under WADA.

Does Body Pharm sell them separately?

No — Body Pharm supplies a combined BPC-157 + TB-500 pre-loaded pen for research use. If your work requires separate per-compound dosing, a fixed blend is the wrong format.

This page is educational and intended for research and informational use only. It is not medical advice, a treatment recommendation, or dosing guidance, and it makes no promises about outcomes. Where a compound has held a marketing authorisation, approved medicines are supplied only through licensed pharmacies with a prescription. Body Pharm EU supplies research-grade materials for laboratory use, not approved medicines, and nothing here should be read as a substitute for advice from a qualified healthcare professional.

Reviewed by the Body Pharm Team · Updated August 2026